EGFR-Mutated Lung Cancer Video Perspectives
Erminia Massarelli, MD, PhD, MS
Massarelli reports receiving honoraria from AstraZeneca and Merck; consulting and/or advising Bristol Myers Squibb Foundation, Genentech/Roche, Janssen Scientific Affairs, Merck, and Sanofi; serving on a speakers' bureau for AstraZeneca; receiving research funding from AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Merck, Pfizer, and Tessa Therapeutics; and receiving travel, accommodations, and expenses from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Merck, and Pfizer.
VIDEO: Evolution of biomarker testing in EGFR-mutated lung cancer
Transcript
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Since the discovery of the EGFR sensitizing mutation in 2004. There's been a lot of finding the research about it. So, we knew before 2004 that there were patient were responding to the EGFR tyrosine kinase inhibitors, initial ones, you know, gefitinib (Iressa; AstraZeneca) and erlotinib (Tarceva; Roche). And they had certain more frequently certain characteristics like Asian women smokers. However, only after the discovery of the EGFR sensitizing mutation, we were able to really tailor treatments to the specific group of patients. And it is fundamental, of course the discovery of EGFR mutation. Of course, you know as of today, an oncologist treating lung cancers today. It is fundamental to order a comprehensive molecular test which done either on the tumor sections, or by blood, you know it’s the liquid biopsy. And they are both very specific to detect EGFR sensitized mutation.
